We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed Acute Myeloid Leukemia (AML) occurs when the cancer returns after treatment. It is a serious condition that affects the blood and bone marrow, leading to symptoms such as fatigue, frequent infections, and easy bruising.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
